SCHEMBL20804319

SCHEMBL20804319

Cc1cccc(CN2C(=O)CCC2=O)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.58
POLB P06746 4/20 0.55
KMT2A Q03164 4/20 0.55
MEN1 O00255 3/20 0.55
L3MBTL1 Q9Y468 1/20 0.51
MAPT P10636 2/20 0.49
KDM4E B2RXH2 1/20 0.49
CYP3A4 P08684 1/20 0.49
RECQL P46063 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
TP53 P04637 1/20 0.49
USP2 O75604 1/20 0.48
LMNA P02545 1/20 0.48
TSHR P16473 1/20 0.48
MAPK1 P28482 1/20 0.48
ATM Q13315 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
ACHE P22303 2/20 0.47
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27383399 0.93 ALDH1A1 (0.55) ALDH1A1POLBKMT2AMEN1L3MBTL1
SCHEMBL27377260 0.81 ATAD2 (0.61) ALDH1A1POLBKMT2AMEN1TP53
SCHEMBL30806785 0.81 ATAD2 (0.61) ALDH1A1POLBKMT2AMEN1TP53
SCHEMBL7224723 0.80 MGLL (0.60) ALDH1A1POLBKMT2AMEN1MAPT
SCHEMBL7462946 0.79 GSK3A (0.67) ALDH1A1POLBKMT2AMEN1MAPT
SCHEMBL28555863 0.79 CYP2C9 (0.65) ALDH1A1KMT2AMEN1MAPTKDM4E
SCHEMBL5766288 0.79 SMN1; SMN2 (0.53) POLBKMT2AMEN1KDM4ETDP1
SCHEMBL6607455 0.79 CA12 (0.47) ALDH1A1POLBKMT2AMEN1NPSR1
SCHEMBL10922984 0.77 KMT2A (0.60) POLBKMT2AMEN1MAPTTDP1
SCHEMBL29819860 0.77 KMT2A (0.60) POLBKMT2AMEN1MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339871-A1 COMPOUNDS AND METHODS OF MODULATING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 METREA BIOSCIENCES INC (US) 2023-10-26 US disclosed
EP-3089962-B1 RADIOIODINATED COMPOUNDS NUTECH VENTURES (US) 2019-03-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339871-A1 COMPOUNDS AND METHODS OF MODULATING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 HSD17B1, HSD17B13, HSD17B11 ALDH1A1 114/4885POLB 389/4885KMT2A 2837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.